Neogen Upgraded to Buy with $12 Target as Q2 Beats Drive 31.6% Rally
Guggenheim upgraded Neogen to a Buy rating, increasing its price target to $12 from $8 following the release of fiscal second-quarter results. The company reported revenue of $224.7M and non-GAAP net income of $22.6M, both beating estimates and triggering a 31.6% stock rally.
1. Guggenheim Upgrade Sparks Rally
On January 9, 2026, Guggenheim lifted its recommendation on Neogen Corporation to a Buy rating and raised its 12-month price target to $12 from $8. This upgrade immediately triggered a surge in investor interest, as market participants responded positively to the firm’s projection of renewed upside potential. Guggenheim cited Neogen’s strong product pipeline in food and animal safety diagnostics and the recent strategic divestiture of non-core assets as key catalysts for improved long-term profitability.
2. Q2 Earnings Outperform Expectations
Neogen reported fiscal second-quarter revenue of $224.7 million, a 2.8% year-over-year decline driven by divestitures and discontinued product lines. However, non-GAAP net income of $22.6 million, or $0.10 per share, modestly trailed last year’s $24.4 million but comfortably exceeded analyst forecasts of roughly $0.03 per share and $208 million in sales. Management highlighted sequential margin expansion, with adjusted EBITDA rising to $56.4 million, or 25% of sales, up from 23% in the prior quarter.
3. Revenue Headwinds and Strategic Responses
Neogen attributed the slight top-line contraction to the sale of its pet care business and the phase-out of legacy testing kits. In response, the company is reallocating resources toward its genomics and rapid-test platforms, which delivered combined quarterly growth of 14%. Leadership affirmed full-year guidance of $845 million to $855 million in revenue and raised adjusted EBITDA targets to $175 million, reflecting confidence in cross-selling opportunities within its core food safety segment.
4. Significant Stock Movement and Valuation Profile
Following the earnings release and Guggenheim upgrade, Neogen’s shares climbed by approximately 31.6% in a single session, marking the largest one-day jump since 2018. Trading volume reached 22.68 million shares, well above the 12-month daily average of 6.3 million. The company’s market capitalization expanded to about $2.11 billion. Over the past year, the stock has traded within a range of $3.87 to $12.98, and the current enterprise-value-to-sales multiple stands near 2.2x, in line with industry peers in the food and animal safety diagnostics space.